WEDNESDAY, Aug. 19, 2015 (HealthDay News) -- People with type 1 diabetes who use insulin pumps seem to have a much lower risk of dying from heart disease or stroke prematurely than those who rely on multiple daily injections of insulin, new research suggests.
"As done in Sweden at the time of this study, insulin pump treatment almost halved cardiovascular mortality," said study author Dr. Isabelle Steineck, from Aarhus University Hospital in Denmark.
The researchers found a 45 percent lower risk of dying from heart disease early for insulin pump users. And the risk of dying early from heart disease or stroke was 42 percent lower for insulin pump users, while the risk of all-cause death was 27 percent lower during the seven-year study period.
Because this was only an observational study, the authors can't say for sure that insulin pumps lowered death risk during the study, although they did find a significant association between these factors.
The findings were published recently in the BMJ. No funding for the study was provided by insulin pump manufacturers, Steineck added.
Type 1 diabetes is a disease that causes the body's immune system to mistakenly attack the insulin-producing cells in the pancreas. Insulin is a hormone that helps the body convert sugar from foods into fuel. People with type 1 diabetes must replace that lost insulin to survive.
There are two basic ways to do this. One is multiple daily injections of insulin. The second option is an insulin pump. An insulin pump delivers insulin through a tiny tube that's inserted under the skin. The person with diabetes programs the pump to tell it how much insulin to deliver and when. Insulin pumps are not fully automated; they still require a lot of input from the person using the pump, the study authors explained.
Type 1 diabetes increases the risk of heart disease and stroke. The risk of dying from heart disease is twice as high for someone with type 1 diabetes compared to someone in the general population, the study authors said.
The study included more than 18,000 people with type 1 diabetes from the Swedish National Diabetes Register. Nearly 2,500 of them used an insulin pump to manage their diabetes, the study said.
Pump users' average age was 38; for those taking injections, it was 41. During an average of almost seven years of follow-up, nearly 1,200 people died, the study found.
Steineck noted that insulin pumps and their supplies are fully covered by insurance in Sweden, although the choice of pumps is limited.
So how might insulin pumps reduce the risk of premature death? It's possible they reduce the number of severe episodes of low blood sugar levels (hypoglycemia), the study authors suggested. Hypoglycemia has been linked to heart disease risk, they said.
It's also possible that the additional education received when switching from injections to an insulin pump may help patients better manage their blood sugar levels, Steineck noted.
"We evaluated the patients who used insulin pump therapy and do not know if the observed effect is attributable to continuous infusion of insulin or that some, if not all, of the effect is attributable to intensified glucose monitoring, increased motivation to control blood glucose, or a better knowledge about having type 1 diabetes," she explained.
One expert said the findings were interesting, but not conclusive.
"Continuous insulin infusion, otherwise known as pump therapy, is a more physiologic approach that has been shown in many analyses to be beneficial," said Vincent Crabtree, director of research business development for JDRF (formerly the Juvenile Diabetes Research Association). "This paper is intriguing, but will need more research to draw definitive conclusions."
Crabtree said that fewer than half of Americans with type 1 diabetes use an insulin pump.
Steineck hopes this new study will help boost those numbers. "Our study is one of many that gives evidence for a greater insurance coverage for insulin pumps," she added.
Learn more about insulin pumps from the American Diabetes Association.
SOURCES: Isabelle Steineck, M.D., Aarhus University, Aarhus, Denmark; Vincent Crabtree, director, research business development, JDRF; June 22, 2015, BMJ
Copyright © 2015 HealthDay. All rights reserved.